Eisai : Investors, patients await FDA decision on Biogen Alzheimer's drug due Monday
U.S. regulators are slated to decided by Monday whether to approve Biogen Inc's controversial Alzheimer's disease drug, and Wall Street analysts and industry observers are deeply divided on its... | June 4, 2021